One of the pioneers of antisense-mediated exon skipping therapy for Duchenne. Currently President of Oligonucleotide Therapeutics society

Dr Reebye is involved in the development of therapeutic gain of function studies using novel RNA activation strategies. His work involves close collaboration with private biotechnology and international academic institutions both in the US and Asia. These versatile and powerful new tools for gene activation has shown an impact in cancer research.